Press release

Zumutor Biologics Selects Teiko for Rapid, Custom Cytometry Panel Development to Support Development of Novel Biologics

Zumutor Biologics has selected Teiko to rapidly develop and validate a custom 42-marker mass cytometry panel to support its novel biologics pipeline. The collaboration includes high-throughput PBMC profiling and data analysis through Teiko’s TokuProfile™ Dashboard, enabling deep immune insights into the mechanism of action and pharmacodynamics of Zumutor’s NK checkpoint therapeutic candidate, ZM008.

PLACEHOLDER_LOAD_FROM_FILE